Cargando…
Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major health concern with no approved pharmacological therapies. Molecules developed to activate the bile acid-receptor TGR5 regulate pathways involved in MALFD pathogenesis, but the therapeutic value of TGR5 activation on the active...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268629/ https://www.ncbi.nlm.nih.gov/pubmed/35807885 http://dx.doi.org/10.3390/nu14132707 |
_version_ | 1784744031467601920 |
---|---|
author | Gillard, Justine Picalausa, Corinne Ullmer, Christoph Adorini, Luciano Staels, Bart Tailleux, Anne Leclercq, Isabelle A. |
author_facet | Gillard, Justine Picalausa, Corinne Ullmer, Christoph Adorini, Luciano Staels, Bart Tailleux, Anne Leclercq, Isabelle A. |
author_sort | Gillard, Justine |
collection | PubMed |
description | Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major health concern with no approved pharmacological therapies. Molecules developed to activate the bile acid-receptor TGR5 regulate pathways involved in MALFD pathogenesis, but the therapeutic value of TGR5 activation on the active form of MAFLD, non-alcoholic steatohepatitis (NASH), still needs to be evaluated. As TGR5 agonism is low in MAFLD, we used strategies to promote the production of endogenous TGR5 ligands or administered pharmacological TGR5 agonists, INT-777 and RO5527239, to study the effect of TGR5 activation on liver and metabolic diseases in high-fat diet-fed foz/foz mice. Although described in the literature, treatment with fexaramine, an intestine-restricted FXR agonist, did not raise the concentrations of TGR5 ligands nor modulate TGR5 signaling and, accordingly, did not improve dysmetabolic status. INT-777 and RO5527239 directly activated TGR5. INT-777 only increased the TGR5 activation capacity of the portal blood; RO5527239 also amplified the TGR5 activation capacity of systemic blood. Both molecules improved glucose tolerance. In spite of the TGR5 activation capacity, INT-777, but not RO5527239, reduced liver disease severity. In conclusion, TGR5 activation in enterohepatic, rather than in peripheral, tissues has beneficial effects on glucose tolerance and MAFLD. |
format | Online Article Text |
id | pubmed-9268629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92686292022-07-09 Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism Gillard, Justine Picalausa, Corinne Ullmer, Christoph Adorini, Luciano Staels, Bart Tailleux, Anne Leclercq, Isabelle A. Nutrients Article Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major health concern with no approved pharmacological therapies. Molecules developed to activate the bile acid-receptor TGR5 regulate pathways involved in MALFD pathogenesis, but the therapeutic value of TGR5 activation on the active form of MAFLD, non-alcoholic steatohepatitis (NASH), still needs to be evaluated. As TGR5 agonism is low in MAFLD, we used strategies to promote the production of endogenous TGR5 ligands or administered pharmacological TGR5 agonists, INT-777 and RO5527239, to study the effect of TGR5 activation on liver and metabolic diseases in high-fat diet-fed foz/foz mice. Although described in the literature, treatment with fexaramine, an intestine-restricted FXR agonist, did not raise the concentrations of TGR5 ligands nor modulate TGR5 signaling and, accordingly, did not improve dysmetabolic status. INT-777 and RO5527239 directly activated TGR5. INT-777 only increased the TGR5 activation capacity of the portal blood; RO5527239 also amplified the TGR5 activation capacity of systemic blood. Both molecules improved glucose tolerance. In spite of the TGR5 activation capacity, INT-777, but not RO5527239, reduced liver disease severity. In conclusion, TGR5 activation in enterohepatic, rather than in peripheral, tissues has beneficial effects on glucose tolerance and MAFLD. MDPI 2022-06-29 /pmc/articles/PMC9268629/ /pubmed/35807885 http://dx.doi.org/10.3390/nu14132707 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gillard, Justine Picalausa, Corinne Ullmer, Christoph Adorini, Luciano Staels, Bart Tailleux, Anne Leclercq, Isabelle A. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title_full | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title_fullStr | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title_full_unstemmed | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title_short | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism |
title_sort | enterohepatic takeda g-protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268629/ https://www.ncbi.nlm.nih.gov/pubmed/35807885 http://dx.doi.org/10.3390/nu14132707 |
work_keys_str_mv | AT gillardjustine enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT picalausacorinne enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT ullmerchristoph enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT adoriniluciano enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT staelsbart enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT tailleuxanne enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism AT leclercqisabellea enterohepatictakedagproteincoupledreceptor5agonisminmetabolicdysfunctionassociatedfattyliverdiseaseandrelatedglucosedysmetabolism |